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1, 7 (3.5%) grade 2 and no grade 3 lesions were observed. 93
(46.5%) BMLs that were seen on the IW TSE FS were not de-
tectable on the DESS. Assessment of BML size was superior for
the sagittal IW TSE FS sequence (P<0.001). 113 cystic lesions
were observed. No signiﬁcant difference was found for differenti-
ation between non-cystic and cystic part of BMLs. In 89 (78.8%)
cases the DESS delineated the cystic lesions superiorly. No differ-
ence between the sequences was seen in 24 (21.2%) cases. The
DESS sequence showed superiority for cyst delineation (p<0.001).
Conclusions: Full extent of non-cystic BMLs is only shown on the
IW TSE FS sequence. The DESS sequence helps in the differ-
entiation of non-cystic vs. cystic parts of BMLs as it depicted the
cyst delineation superiorly. Both sequences are complementary,
but size of BMLs should only be assessed on the IW TSE FS
sequence.
Semiquantitative assessment of non-cystic subchondral bone mar-
row lesions should be performed on sequences that depict these
lesions to their maximum extent.
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Purpose: The absence of a proxy biomarker for measurement of
structural progression of knee OA has been a major impediment to
development of disease-modifying interventions for this common,
disabling disorder. Several novel technological approaches have
emerged with the potential to measure changes in articular carti-
lage. Two of these include T1-mapping of cartilage after contrast
administration (delayed Gadolinium Enhanced MRI of Cartilage,
dGEMRIC) and T2-mapping.
We performed a pilot study to test ability of these parameters
to detect changes in cartilage characteristics in human knee OA
following a 24-week course of oral proprietary collagen hydrolysate
Fortigel®. This is a nutritional product produced by GELITA shown
to have anabolic effects on chondrocytes in-vivo and reduce
progression of OA in animal models.
Methods: We performed a randomized, placebo-controlled,
double-blind, 24-week clinical trial of 10 grams collagen hy-
drolysate orally once per day among 30 participants with symp-
tomatic knee OA. There was a planned option for a further 24-week
extension of the clinical trial based on a blinded assessment (A
vs. B) of the 24-week data by the study Data & Safety Monitoring
Board. Fortigel® and placebo formulations were indistinguishable
in appearance and ﬂavor. Treatment assignment was according
to a blocked randomization scheme, stratiﬁed by body mass in-
dex (BMI). We permitted participants to take acetaminophen or
non-steroidal anti-inﬂammatory drugs at their regular dose and
tramadol for breakthrough pain. Participants received clinical as-
sessment every 8 weeks and dGEMRIC and T2 MRI scans at
baseline, 24 and 48 weeks. dGEMRIC index and T2 values were
calculated in 6 speciﬁed regions of interest in cartilage. The
primary outcome was change in dGEMRIC index in the study
knee hyaline cartilage. Secondary endpoints included change in
cartilage mean T2 relaxation time, WOMAC scores, timed walk
and chair stand tests. We tested for differences between groups
using a Wilcoxon Rank Sum (non-parametric) test since there
was evidence of a non-normality of distribution of study out-
comes.
Results: The assignment groups were balanced in most respects
but the placebo group had slightly more functional limitation (table
1). The DSMB recommended continuation for the full 48 weeks.
During the ﬁrst 24 weeks, the dGEMRIC indices in the medial
and lateral tibial regions fell in the placebo group but increased in
the treatment group (table 2). Signiﬁcant trends were not seen for
other regions of interest or T2 values. The clinical indices broadly
improved in both groups without any major differences between
them (e.g. change in WOMAC pain at 24 weeks: -1.4 versus
-1.5, p=ns). Analysis of the 48-week outcomes showed no further
change.
Table 1. Demographics and baseline characteristics of participants
Placebo (n=15) CH (n=15)
Age, y, mean (SD) 60.3 (8.5) 58.9 (8.0)
Gender, female, n (%) 9 (60%) 9 (60%)
Race, white, n (%) 13 (87%) 14 (93%)
BMI, kg/m2, mean (SD) 31.1 (7.2) 29.9 (4.6)
KL score = 2, n (%) 13 (87%) 14 (93%)
dGEMRIC Index, msec (SD)
Medial Tibia 408 (80) 366 (81)
Central Medial Femur 413 (80) 421 (56)
Posterior Medial Femur 425 (74) 435 (62)
Lateral Tibia 450 (89) 426 (89)
Central Lateral Femur 414 (76) 430 (67)
Posterior Lateral Femur 400 (52) 414 (83)
WOMAC (SD)
Pain 5.8 (3.0) 4.6 (2.6)
Stiffness 2.8 (1.5) 2.9 (1.1)
Function 20.6 (10.9) 12.9 (8.7)*
Total 29.2 (13.9) 20.3 (10.5)
20-meter walk, median, sec 17.9 16.2
Chair stand, sec (SD) 17.7 (5.9) 14.7 (3.5)
Table 2. Median Change in dGEMRIC Index from Baseline to 24 and 48 weeks
Placebo Group CH Group
0-24 weeks 0-48 weeks 0-24 weeks 0-48 weeks
Medial Tibia -38.0 14.0 28.0* 47.0
Lateral Tibia -33.5 -1.0 40.0* 28.0
Central Medial Femur 21.0 -5.0 -18.0 17.0
Posterior Medial Femur 22.5 -6.0 26.0 15.0
Central Lateral Femur 26.0 2.0 -17.0 -6.0
Posterior Lateral Femur 30.5 19.0 36.0 32.0
*Between group p-value <0.05.
Conclusions: In summary, the dGEMRIC index was able to dis-
criminate between treatment and placebo groups in the tibial
regions. The directionality of this change is compatible with an
increase in proteoglycan content of hyaline cartilage in those re-
ceiving Fortigel® and a decrease among those on the placebo.
The sample size was small, so these data should be regarded as
preliminary.
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Purpose: Early degenerative changes in articular cartilage leading
to osteoarthritis are accompanied by glycosaminoglycan (GAG)
depletion in the cartilage matrix. Subjects with prior tears to the
anterior cruciate ligament (ACL) may show early development
of osteoarthritis. Sodium MRI has been shown to correlate with
GAG concentration, and may be useful in detecting and tracking
early GAG depletion. Sodium MRI is challenging due to relatively
